NASDAQ:MYL - Mylan Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$30.04 -0.37 (-1.22 %)
(As of 12/14/2018 09:09 AM ET)
Previous Close$30.41
Today's Range$29.8250 - $30.72
52-Week Range$29.10 - $47.82
Volume3.41 million shs
Average Volume3.87 million shs
Market Capitalization$15.68 billion
P/E Ratio6.59
Dividend YieldN/A
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; anti-retroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology, oncology, and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and Dymista, which is used for the treatment of seasonal allergic rhinitis. Further, it markets OTC products, including Cold-EEZE, Midnite, and Vivarin. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, group purchasing organizations, and government entities; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. Mylan N.V. has collaboration and license agreements with Pfizer Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., and Biocon Ltd. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:MYL
Previous Symbol


Debt-to-Equity Ratio1.20
Current Ratio1.26
Quick Ratio0.77


Trailing P/E Ratio6.59
Forward P/E Ratio6.45
P/E Growth1

Sales & Book Value

Annual Sales$11.91 billion
Price / Sales1.30
Cash Flow$7.8229 per share
Price / Cash Flow3.84
Book Value$24.81 per share
Price / Book1.21


EPS (Most Recent Fiscal Year)$4.56
Net Income$696 million
Net Margins4.71%
Return on Equity19.39%
Return on Assets7.15%


Outstanding Shares515,630,000
Market Cap$15.68 billion

Mylan (NASDAQ:MYL) Frequently Asked Questions

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

How were Mylan's earnings last quarter?

Mylan NV (NASDAQ:MYL) announced its earnings results on Monday, November, 5th. The company reported $1.25 EPS for the quarter, beating analysts' consensus estimates of $1.19 by $0.06. The company earned $2.86 billion during the quarter, compared to the consensus estimate of $2.91 billion. Mylan had a return on equity of 19.39% and a net margin of 4.71%. The firm's revenue for the quarter was down 4.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.10 earnings per share. View Mylan's Earnings History.

When is Mylan's next earnings date?

Mylan is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Mylan.

What price target have analysts set for MYL?

18 brokerages have issued 12-month target prices for Mylan's stock. Their predictions range from $31.00 to $59.00. On average, they anticipate Mylan's share price to reach $46.5625 in the next twelve months. This suggests a possible upside of 55.0% from the stock's current price. View Analyst Price Targets for Mylan.

What is the consensus analysts' recommendation for Mylan?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mylan.

What are Wall Street analysts saying about Mylan stock?

Here are some recent quotes from research analysts about Mylan stock:
  • 1. Cantor Fitzgerald analysts commented, "We rate MYL as 12-month price target of $41. We like the company, and there are a lot of potentially positive catalysts coming up. That said, the risk reward is already reflected in the stock’s valuation, in our view. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to calculate our 12- month price target of $41." (11/20/2018)
  • 2. According to Zacks Investment Research, "Mylan's generic business in the United States continues to experience pricing and competitive pressure. The competitive pressure for EpiPen has increased further along with supply issues. Mylan suffered a setback when the FDA refused to approved its generic version of asthma drug, Advair Diskus. While the biosimilar business continues to gain traction buoyed by new approvals, it might not be enough to combat the persistent decline in North America. Challenges in North America has prompted the management to evaluate strategic alternatives. Concurrent with the second-quarter results, Mylan lowered its outlook as a result of the change in expected complex product launch and utilization assumptions and resizing of product opportunities in the United States, and the negative impact on operations of the restructuring and remediation program in Morgantown. Shares have underperformed the industry in the year so far." (10/9/2018)
  • 3. Guggenheim analysts commented, "We spoke with two oncologists in different practice settings regarding their potential use of Fulphila. While biosimilar financial incentives will play a role in Fulphila’s adoption, the Onpro device appears entrenched in current clinical practice. For that and other reasons, we believe that it might be more prudent to take a conservative approach to Fulphila’s uptake at the outset. We maintain our BUY rating on shares of Mylan. Consultant Commentary: We spoke with two oncologists on their respective academic and rural private practice settings. The academic consultant saw roughly 100 Neulasta patients per month while the rural oncologist saw ~30 Neulasta patients per month." (6/14/2018)

Has Mylan been receiving favorable news coverage?

Media stories about MYL stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mylan earned a news impact score of 1.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.

Are investors shorting Mylan?

Mylan saw a decrease in short interest during the month of November. As of November 15th, there was short interest totalling 7,948,825 shares, a decrease of 19.0% from the October 31st total of 9,808,231 shares. Based on an average daily trading volume, of 7,409,055 shares, the short-interest ratio is currently 1.1 days. Currently, 1.6% of the shares of the stock are short sold. View Mylan's Current Options Chain.

Who are some of Mylan's key competitors?

Who are Mylan's key executives?

Mylan's management team includes the folowing people:
  • Ms. Heather Bresch, CEO & Exec. Director (Age 49)
  • Mr. Rajiv Malik, Pres & Exec. Director (Age 57)
  • Mr. Kenneth S. Parks, Chief Financial Officer (Age 55)
  • Mr. Daniel M. Gallagher Jr., Chief Legal Officer (Age 45)
  • Mr. Anthony Mauro, Chief Commercial Officer (Age 45)

Who are Mylan's major shareholders?

Mylan's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc (6.94%), Pzena Investment Management LLC (4.20%), Bank of New York Mellon Corp (1.98%), First Pacific Advisors LP (1.81%), Capital World Investors (1.49%) and Menora Mivtachim Holdings LTD. (1.40%). Company insiders that own Mylan stock include Anthony Mauro, Heather M Bresch, Laboratories Abbott, Paul Campbell, Rajiv Malik and Robert J Coury. View Institutional Ownership Trends for Mylan.

Which major investors are selling Mylan stock?

MYL stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., JPMorgan Chase & Co., JPMorgan Chase & Co., Migdal Insurance & Financial Holdings Ltd., Jennison Associates LLC, Partner Fund Management L.P. and Mitsubishi UFJ Trust & Banking Corp. Company insiders that have sold Mylan company stock in the last year include Anthony Mauro, Heather M Bresch, Paul Campbell, Rajiv Malik and Robert J Coury. View Insider Buying and Selling for Mylan.

Which major investors are buying Mylan stock?

MYL stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Clearbridge Investments LLC, Bank of New York Mellon Corp, Pictet Asset Management Ltd., Pzena Investment Management LLC, Vanguard Group Inc, Sphera Funds Management LTD. and Dimensional Fund Advisors LP. View Insider Buying and Selling for Mylan.

How do I buy shares of Mylan?

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mylan's stock price today?

One share of MYL stock can currently be purchased for approximately $30.04.

How big of a company is Mylan?

Mylan has a market capitalization of $15.68 billion and generates $11.91 billion in revenue each year. The company earns $696 million in net income (profit) each year or $4.56 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

What is Mylan's official website?

The official website for Mylan is

How can I contact Mylan?

Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000 or via email at [email protected]

MarketBeat Community Rating for Mylan (NASDAQ MYL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  651 (Vote Outperform)
Underperform Votes:  507 (Vote Underperform)
Total Votes:  1,158
MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe MYL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel